Skip to content

argenx NV ADR Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 22, 2026 results vs estimates

argenx NV ADR · E.ARGX.NASDAQ · United States
Use symbol E.ARGX.NASDAQ in our API & Excel add-in to retrieve this data ↓
897.85
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 0%
Trend 50%
Bubble Risk LOW
Realised Volatility (20D) 53.83%

argenx NV ADR Forecast

argenx NV ADR short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is positive (6 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 53.8% a year, a typical one-standard-deviation range is 829.77–965.93 over a week, 758.33–1,037 over a month and 414.55–1,381 over a year. (Signals as of 1 Nov 2026.)

argenx NV ADR Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
argenx NV ADR
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
argenx NV ADR
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
argenx NV ADR
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for argenx NV ADR, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on argenx NV ADR

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

argenx NV ADR Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to argenx NV ADR; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How argenx NV ADR’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how argenx NV ADR behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About argenx NV ADR (United States)

argenx NV ADR is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Argen-X

Frequently asked questions

What is argenx NV ADR?
argenx NV ADR is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest argenx NV ADR price?
The latest close is 897.85 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is argenx NV ADR in an uptrend?
As of 1 Nov 2026, short-term momentum is neutral (2 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is positive (6 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is argenx NV ADR?
20-day realised volatility is 53.8% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 15.5% over a month and 7.6% over a week.
What factors affect argenx NV ADR?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to argenx NV ADR, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade argenx NV ADR?
58 backtested tactical asset allocation strategies trade argenx NV ADR through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are argenx NV ADR returns analysed?
The Statistical Distribution of Returns section shows the distribution of argenx NV ADR daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free argenx NV ADR historical data?
In the Free historical data section of this page: the last 10 years of argenx NV ADR daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free argenx NV ADR historical data (last 10 years)

Browse or instantly download the last 10 years of argenx NV ADR daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ARGX.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20925.7
2026-11-19942.04
2026-11-18941.25
2026-11-17947.52
2026-11-16950.95
2026-11-13960.04
2026-11-12981.33
2026-11-11977.58
2026-11-10971.55
2026-11-09962.27
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.